Zikon

Quick links to important sections

Zikon

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zikon

What is Zikon? (Overview)

Property Description
Active ingredient Azithromycin
Form Tablets, Capsules, Oral Suspension, Powder for IV Solution
Pharmacological class Azalide Macrolide Antibiotic
Common use Systemic treatment of bacterial infections, often in shorter courses
Origin Semi-synthetic derivative

What Type of Medicine is Zikon?

Zikon is a trade name for a prescription-only antibiotic medicine containing the active ingredient Azithromycin. It is classified as an azalide macrolide, a subclass of the larger macrolide family, distinguished by the incorporation of a nitrogen atom into its chemical structure. This semi-synthetic derivative of Erythromycin is clinically recognized for its ability to provide a powerful systemic antimicrobial action against a wide range of bacterial pathogens. The medication is a single active ingredient product.


Azithromycin: Composition and Forms

Azithromycin is formulated with essential pharmaceutical excipients to create its various medicinal products. This medicine is available in multiple dosage forms, including tablets and capsules for oral administration, as well as a specialized powder for solution used for intravenous (IV) preparation. The availability of an oral suspension form makes it suitable for treating patients, such as children, who may have difficulty swallowing solid medication.


What is the General Purpose of Zikon?

The general purpose of Zikon is to provide broad-spectrum defense by eliminating harmful bacteria responsible for infection. This is achieved because Azithromycin acts as a protein synthesis inhibitor, binding to the bacterial ribosome to stop the bacteria from growing and replicating. A key differentiating feature is its long tissue half-life, which allows the medicine to remain active for an extended period after the last dose, a unique pharmacokinetic property that enables shorter treatment courses compared to many other antibiotics.

Regulatory References

  1. Azithromycin Mechanism of Action (StatPearls)

What side effects are possible with Zikon?

Possible Side Effects and Safety Information

The official safety profile of Zikon (Azithromycin) classifies potential adverse reactions based on their frequency and the system-organ class affected, as documented in governmental regulatory sources. These effects range from very common, frequently observed events to rare, serious concerns.


Adverse Reaction Categories and Frequency

The most frequently observed adverse reactions are primarily related to the gastrointestinal system and often occur at the start of therapy.

Classification Examples of Documented Effects
Very Common Diarrhea, loose stools
Common Headache, nausea, abdominal pain, vomiting
Uncommon Dizziness, candidiasis, rash, pruritus

Serious Adverse Reactions

Official labeling documents certain rare but clinically significant adverse reactions. These include a risk of QT interval prolongation and potentially life-threatening cardiac arrhythmias, such as Torsade de Pointes. Severe hepatobiliary disorders, including hepatic failure and cholestatic jaundice, have been reported. The medicine is also associated with severe cutaneous reactions, such as DRESS syndrome and Stevens-Johnson Syndrome (SJS), and Clostridioides difficile-associated diarrhea (CDAD), which can occur even long after treatment ends.


Population and Safety Constraints

Safety notes address specific patient groups and conditions. The medicine is contraindicated in individuals with known hypersensitivity to azithromycin, erythromycin, or any macrolide, or a history of drug-associated cholestatic jaundice. Caution is advised for patients with pre-existing cardiac conditions, and reports exist of symptom exacerbation in patients with Myasthenia Gravis. The label also notes reported cases of Infantile Hypertrophic Pyloric Stenosis (IHPS) following use in neonates.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of an opioid, or a suspected overdose, is officially classified as a life-threatening medical emergency and is manifested by severe complications affecting the respiratory and central nervous systems. These critical presentations include respiratory depression (slowed or shallow breathing, or no breathing) and central nervous system (CNS) depression, which can lead to profound sedation, stupor, coma, and ultimately, death or permanent brain damage.

Required Emergency Actions

The product (Zikon) is intended for immediate administration as an emergency therapy in the event of a known or suspected opioid overdose in adult and pediatric patients. Regulatory documents explicitly state that the product must be administered as quickly as possible because prolonged respiratory depression is known to result in severe central nervous system injury or fatality. Users are instructed to administer the initial dose and then immediately seek emergency medical assistance.

Risk of Recurrence

A critical note in the overdose information is the risk of recurrent respiratory and CNS depression. This is because the duration of action of the reversal agent may be shorter than that of the opioid causing the overdose. The patient must be kept under continuous surveillance until emergency medical personnel arrive. If the patient responds to the initial dose but then relapses back into respiratory or CNS depression, an additional dose should be administered.

Therapeutic Uses of Zikon

What Zikon Treats: Main Uses and Benefits

Zikon is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. It is relevant in conditions characterized by periods of heightened symptoms associated with bacterial processes. The medicine is relevant in contexts involving heightened systemic burden across several therapeutic areas.

The medication is commonly used to help with conditions presenting with acute episodes, including community-acquired pneumonia, acute bacterial exacerbations of COPD, sinusitis, acute otitis media, uncomplicated skin structure infections, and specific sexually transmitted infections like Chlamydia trachomatis.

Quick Fact: Relief for Systemic Discomfort

Zikon contributes to easing the overall symptom load by supporting the patient during difficult episodes of fever, cough, and localized inflammatory pain. The core therapeutic benefit is to address symptom clusters that may become intense or disruptive, contributing to improved day-to-day comfort when symptoms are more noticeable. This is relevant when supportive symptom management is appropriate in scenarios where additional management of discomfort is required.

Eligibility and Restrictions for Use

Zikon's eligibility is strictly defined by regulatory documents, distinguishing approved patient populations from those who must not use the medicine.

Contraindicated Populations

Zikon is absolutely prohibited for use in patients with:

  • Known hypersensitivity to azithromycin, erythromycin, or any macrolide/ketolide antibiotic.
  • A history of cholestatic jaundice or hepatic dysfunction specifically associated with previous azithromycin use.

Age-Based Limitations and Restrictions

Population Eligibility Status Special Caution/Restriction
Adults & Older Adults Approved for use. Older adults may be more susceptible to cardiac risk (QT prolongation).
Pediatric Patients Approved for most uses at 6 months of age and older. Safety and effectiveness are not established for infants under 6 months.
Neonates (Up to 42 days) Restricted. Use has been associated with reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).

Conditional Use and Comorbidities

Use of Zikon requires caution or is not recommended for patients with:

  • Severe Hepatic or Renal Impairment (GFR < 10 mL/min).
  • Existing proarrhythmic heart conditions (e.g., known QT prolongation or severe cardiac insufficiency).
  • Myasthenia Gravis, due to the potential for symptom exacerbation.
  • Severe Pneumonia or infections inappropriate for oral therapy (e.g., requiring hospitalization).

During pregnancy, Zikon should only be used if clinically needed and if the benefit outweighs potential risk. It is secreted into breast milk, requiring careful assessment of the infant's exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zikon (Azithromycin) has officially documented interaction patterns that are classified based on pharmacokinetic effects, pharmacodynamic risks, and administration requirements. This medicine is contraindicated with Pimozide due to the potential for inhibition of its metabolism, which carries a documented risk of QTc prolongation and lethal arrhythmias.

Co-administration with other medicinal products known to prolong the QT interval carries an additive pharmacodynamic risk of Torsades de pointes and requires regulatory caution. A pharmacokinetic interaction occurs with the HIV protease inhibitor Nelfinavir, which results in significantly increased azithromycin serum concentrations ( C max and AUC). Additionally, the co-administration with the anticoagulant Warfarin may potentiate its effects, necessitating close monitoring of Prothrombin Time/INR.

Administration Constraints

To prevent a documented reduction in Azithromycin's peak serum concentration ( C max), oral Zikon must be administered at least 1 hour before or 2 hours after administration of aluminum- or magnesium-containing antacids. For the oral suspension form, regulatory documents state that the medicine can be taken with or without food. Population-specific data notes that Azithromycin exposure is slightly altered in patients with mild to moderate renal impairment.

Mechanism of Action

Zikon is a synthetic peptide that works by selectively blocking neuronal N-type voltage-gated calcium channels ( Ca V2.2). These channels are highly concentrated on the pre-synaptic nerve terminals of primary afferent (sensory) neurons within the dorsal horn of the spinal cord.

By physically obstructing the ion-conducting pore of the Ca V2.2 channels, Zikon prevents the necessary influx of calcium ions ( Ca^2+) into the nerve ending. This targeted inhibition halts the calcium-dependent process of exocytosis, which is the biochemical trigger for the release of pronociceptive neurotransmitters, primarily glutamate and Substance P. This mechanism interrupts the flow of nociceptive input within the dorsal horn circuitry. The modification of this early molecular step in the signaling cascade results in altered patterns of neuronal excitability and supports a modulated state within targeted spinal cord pathways.

Dosage and Administration Information

How Zikon is Used: Official Administration Guidelines

Zikon (Azithromycin) is used according to strict, standardized instructions to ensure proper administration. The correct use is determined by the dosage form, the administration route, and the specified course duration.


Official Administration Summary

Usage Domain Official Instruction
Administration Routes Oral (Tablets, Capsules, Suspensions) and Intravenous (IV) (Powder for solution). IV use is typically reserved for initial treatment in severe infections.
Standard Dosing Pattern Short courses are standard, such as a 5-day regimen (500 mg on Day 1, then 250 mg once daily) or a 3-day regimen (500 mg once daily). A single 1-gram dose is used for specific conditions.
Frequency & Duration Dosing is generally once daily (qDay) for multi-day courses, with the maximum duration in common use typically not exceeding 10 days.
Timing Relative to Food Standard oral tablets and suspensions can be taken with or without food. Extended-release oral suspension must be taken on an empty stomach (e.g., at least 1 hour before a meal).

Special Procedural Requirements

IV Preparation: The powder for intravenous solution must be reconstituted and diluted prior to infusion to reach a final concentration that must be infused over a period of 1 to 3 hours, depending on the concentration. The intravenous form must not be administered as a rapid injection or bolus.

Population Rules: Dosing for pediatric patients is determined based on weight (mg/kg). No dose adjustment is required for older adults or for individuals with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zikon (Azithromycin)

The clinical evaluation of Zikon (Azithromycin) was conducted through various scientific methodologies, including Randomized Controlled Trials (RCTs), comparative studies, and large-scale meta-analyses. The research examined different treatment durations and compared Zikon against placebo or other standard medicines to explore outcomes related to symptom evolution and how symptoms are measured in specific conditions. Study results reflect the specific conditions under which they were conducted and do not provide individual predictions.


Evidence for Treating Respiratory and Chest Infections (Pneumonia and COPD Exacerbations)

Research exploring outcomes for respiratory infections has mainly focused on examining outcomes describing episodic or acute changes and monitoring changes in the systemic status of patients during the acute phase of illness.

Clinical evaluation for Community-Acquired Pneumonia (CAP) included RCTs and observational studies in hospitalized and outpatient adults, and in children. Researchers monitored outcomes related to physical discomfort and how symptoms evolved and tracked major outcomes such as hospital stay duration and mortality. Studies report how symptoms evolved and what measurements of acute changes were observed upon completion of the defined treatment course. However, research is ongoing to fully understand the potential impact of increasing rates of macrolide resistance, which may affect treatment reliability.

Evidence for Treating Localized and Specific Infections (Skin and STIs)

Short-term comparative trials were used to evaluate Zikon for Acute Bacterial Sinusitis and Uncomplicated Skin and Skin Structure Infections (SSSI). Outcomes examined included measurements of outcomes related to episodic or acute changes and the tracking of outcomes related to how symptoms evolved. In STI research, specifically for organisms like Chlamydia trachomatis, RCTs monitored outcomes monitoring physiological strain or stress after a single-dose regimen. The evidence is confined to a narrow spectrum of specific, sensitive organisms.


Long-Term and Maintenance Evidence

Zikon has been the subject of dedicated large-scale, long-term RCTs specifically to evaluate its continuous use in patients with moderate to severe COPD who experience frequent exacerbations. These studies monitored outcomes reflecting daily functioning or activity level, measured the change in the annualized rate of acute exacerbations, and tracked changes in pulmonary function measures over periods of 12 months or more. The research provides context, but it also notes that sustaining these observed effects requires consistent, long-term administration was observed in some studies. A key area of uncertainty is the documented concern regarding the potential for promoting long-term antimicrobial resistance.


What Remains Uncertain or Requires Further Research

The results apply only to the populations studied, meaning findings do not necessarily extend to patients with highly complicated infections. Follow-up durations were limited in many of the acute-phase trials, providing less insight into the long-term stability of the resolution or recurrence patterns. Comparative evidence against some newer antibiotic classes is also an area where research is ongoing.

Key Studies & References

  1. Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease (MACRO Study)
  2. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease (COPD and Bronchiectasis)

Frequently Asked Questions (FAQ)

Common questions about Zikon (FAQ)


Q: How long does Zikon typically take to start working?

Official patient information indicates that Zikon begins working shortly after the initial dose. Due to its mechanism as an antibiotic, patients may begin to feel effects relevant to the condition within the first few days of starting the defined course of treatment.


Q: If I stop taking Zikon, are there any immediate effects?

Regulatory guidance focuses on completing the full prescribed course of Zikon. Stopping the medicine prematurely or missing doses may lead to the infection not being fully eliminated and can contribute to the development of antibiotic resistance.


Q: Does Zikon cause weight gain or weight loss?

Official post-marketing surveillance data includes weight loss as a documented adverse event, although this is not common. Weight gain, however, is not explicitly listed among the adverse reactions reported in the regulatory documents.


Q: What if I miss taking a scheduled use of Zikon?

Official patient instructions describe the regulatory procedure for a missed dose, which involves taking the dose if remembered soon after, or skipping it if the next scheduled time is near. Instructions caution against using extra medicine to make up for a dose that was not used.


Q: What if Zikon doesn't seem to be helping after a few weeks?

According to official patient information, if your symptoms do not begin to improve or if they worsen after starting Zikon, official patient information advises contacting the prescribing healthcare provider for evaluation.


Q: Is Zikon used for any conditions other than the main one listed?

Yes, the official indications for Zikon cover a range of bacterial infections. This includes conditions of the respiratory tract (such as pneumonia), specific skin infections, and certain sexually transmitted infections, as defined in regulatory documents.


Q: Is Zikon safe to use if I have a history of heart problems?

Official regulatory documents indicate that caution is required regarding Zikon use in patients with pre-existing heart problems. This is due to the documented risk of cardiac arrhythmias, such as QT prolongation, in susceptible individuals.


Q: Does Zikon have any effect on blood pressure?

Official post-marketing data has reported dizziness, faintness, or lightheadedness upon changing positions. This type of reaction is sometimes associated with a temporary drop in blood pressure (orthostatic hypotension), though it is reported as an event of unknown incidence.


Q: Why is Zikon described as a '[Specific Drug Class]'?

Zikon is officially classified as an azalide macrolide antibiotic. This classification places it within the macrolide antibiotic family, but the term 'azalide' highlights the specific chemical distinction of a nitrogen atom incorporated into its structure.


Q: Is Zikon used for short periods only, or is it for long-term use?

While Zikon is primarily known for its short-term courses (typically a few days) for acute infections, official clinical research has also examined its long-term, low-dose administration for patients with chronic respiratory conditions like COPD exacerbations. Long-term use is typically administered under the supervision of a healthcare professional, as noted in clinical studies.


Q: What does 'clinical evidence' mean when discussing Zikon?

When discussing Zikon, clinical evidence refers to the formal findings generated from structured human research studies. These studies, such as Randomized Controlled Trials (RCTs), are essential for evaluating the medicine's effects and safety profile on patient outcomes, as required by regulatory bodies.


Q: Why do some people need to avoid Zikon?

Official documents state that Zikon is absolutely prohibited (contraindicated) for individuals with a known hypersensitivity to the medicine or related antibiotics (macrolides). It must also be avoided if a patient has a history of specific, severe liver problems that occurred after previous use of Zikon.


Q: Is it true that Zikon can interact with alcohol?

Regulatory documents do not specifically list a direct or dangerous chemical interaction between Zikon and alcohol. However, it is noted that consuming alcohol may potentially worsen some of the medicine’s common side effects, such as dizziness or nausea.


Q: Does Zikon have a risk of dependence or withdrawal effects?

Regulatory information does not describe a risk of dependence or a typical withdrawal syndrome associated with Zikon. However, a serious side effect known as Clostridioides difficile-associated diarrhea can occur, sometimes even long after the treatment has finished.


Q: Is Zikon appropriate for people with liver issues?

Official guidance states that Zikon is contraindicated for individuals with a history of severe liver dysfunction specifically linked to previous azithromycin use. Caution is also advised when using the medicine in patients with pre-existing severe hepatic impairment (severe liver damage).


Q: What conditions make a person 'ineligible' to use Zikon?

The strictest reasons for ineligibility are a documented, severe allergic reaction to the medicine or related antibiotics, or a history of specific liver damage following prior use. Other conditions, such as severe heart or kidney problems, require regulatory caution or assessment but do not automatically prohibit use.


Q: Are there any specific foods or drinks that should be avoided while using Zikon?

Regulatory documents specify two key conditions related to food/drinks. The extended-release oral suspension form is indicated to be taken on an empty stomach. Additionally, the oral forms require a separation of at least 1–2 hours from antacids containing aluminum or magnesium to prevent an interaction.


Q: Can Zikon affect my ability to drive or operate machinery?

The adverse event profile for Zikon includes side effects such as dizziness and headache. It is important for individuals using Zikon to be aware of their personal response to the medicine before driving or operating machinery.


Q: How often do people generally need to use Zikon?

For most approved multi-day treatment courses, Zikon is prescribed for use once daily (qDay). The total duration of therapy is typically a short course, often ranging from 3 to 10 days, depending on the specific infection being treated.


Q: Are there any known long-term expectations for using Zikon?

When long-term use of Zikon is administered, it is often accompanied by regular professional monitoring due to potential side effects and the risk of developing antimicrobial resistance. Furthermore, specific official warnings exist concerning long-term use in certain high-risk patient populations.


Q: Can Zikon be used during pregnancy or while breastfeeding?

Official product information states that during pregnancy, Zikon should only be used if the potential benefit is determined to outweigh the potential risks. The medicine is known to be secreted into breast milk, and official guidance emphasizes that this situation necessitates a careful assessment of the infant's exposure.


Q: Does Zikon affect sleep patterns?

Although not frequently observed, trouble sleeping (insomnia) is listed in the official post-marketing reports for Zikon as an adverse reaction. These reports collect information on side effects that occur after a medicine has been introduced to the market, and the incidence of this effect is currently unknown.


Q: Are there any warnings about Zikon and mental health changes?

Official post-marketing surveillance documents have reported rare psychiatric reactions associated with Zikon, including instances of agitation, anxiety, and aggression. Any unusual changes in mood or behavior are advised to be reported to the prescribing healthcare provider.


Q: What does 'pharmacovigilance' mean in relation to Zikon?

Pharmacovigilance is the official process dedicated to monitoring the safety of Zikon once it is available to the public. This process involves the detection, assessment, and prevention of adverse effects and other drug-related problems to ensure the medicine remains safe in real-world use.


Q: What is the expected duration of the effects of Zikon after it is used?

Zikon is known for a unique pharmacokinetic property called a long tissue half-life. This means the medicine remains active in the body for an extended period even after the last dose is taken, which is why shorter treatment courses are often prescribed.


Q: What happens if Zikon is used for longer than initially planned?

Using Zikon for a duration longer than prescribed increases the risk of specific side effects and significantly increases the risk of developing antibiotic resistance. Regulatory warnings also exist concerning the use of the medicine beyond standard duration in certain vulnerable populations.


Q: Does Zikon need to be used at the same time every day?

Official patient instructions suggest using Zikon around the same time every day to help ensure consistent medicine levels in the body and to improve patient adherence to the full treatment course.


Q: Can Zikon cause skin reactions or rashes?

Yes, official documents note that Zikon can cause skin reactions. Rash and itching (pruritus) are listed as uncommon adverse reactions. Furthermore, rare but serious skin conditions, such as Stevens-Johnson Syndrome (SJS), have been reported in official safety documentation.

How should Zikon be stored and disposed of?

How to Store and Dispose of Zikon

Official labeling requires specific conditions to maintain the stability of Zikon, an Azithromycin-containing medicine.


Storage Requirements

Solid Forms (Tablets/Capsules): Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, tightly closed, and protected from excessive heat, moisture, and light.

Liquid Forms (Oral Suspension): The reconstituted suspension must not be frozen. Standard formulations must be discarded after 10 days. The medicine must be stored out of the sight and reach of children.


Disposal Instructions

Do not dispose of unused or expired Zikon by flushing it down the toilet or throwing it into wastewater. The preferred method is to utilize an official drug take-back program or return the unused product to a pharmacy. Disposal must be conducted in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zikon found in:

A-Z Index: